# US 2021/0330630 A1 · Rivastigmine patch for long-term administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330630 A1
- Document ID: US20210330630A1
- Status: Published application
- Kind: A1
- Application number: 17/271,638
- Filed: 2019-08-30
- Published: 2021-10-28
- Earliest claimed: 2018-08-31
- Assignees: SK Chemicals Co., Ltd.
- Applicants: SK Chemicals Co., Ltd.
- Inventors: Namho KIM; Wonjae CHOI; Hunseung YOO; Soo Min LEE; Yeo-Jin PARK; Sung-Hyuk KIM; Jong-su YOO; Young-me LEE
- Web page: https://patentgrep.com/patent/US20210330630A1

## CPC

- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 47/02: Inorganic compounds
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

## Claims

### Claim 1

A rivastigmine patch for transdermal treatment comprising a backing film; a rivastigmine matrix layer comprising rivastigmine or a pharmaceutically acceptable salt thereof; a self-adhesive matrix layer comprising an adhesive that adheres to the skin; and a release liner that is removed before use,
wherein the content per patch area of the rivastigmine or a pharmaceutically acceptable salt thereof is 2 to 15 mg/cm2 based on the rivastigmine free base, and
the rivastigmine matrix layer comprises hydrophobic silica.

### Claim 2 (depends on 1)

The rivastigmine patch of claim 1, wherein the content per patch area of the rivastigmine or a pharmaceutically acceptable salt thereof is 3.6 to 10.8 mg/cm2 based on the rivastigmine free base.

### Claim 3 (depends on 2)

The rivastigmine patch of claim 2, wherein the content per patch area of the rivastigmine or a pharmaceutically acceptable salt thereof is 5.4 to 9 mg/cm2 based on the rivastigmine free base.

### Claim 4 (depends on 1)

The rivastigmine patch of claim 1, wherein the hydrophobic silica is a hydrophobic fumed silica.

### Claim 5 (depends on 1)

The rivastigmine patch of claim 1, wherein the content of the hydrophobic silica is 10-50% by weight based on the total weight of the rivastigmine matrix layer.

### Claim 6 (depends on 5)

The rivastigmine patch of claim 5, wherein the rivastigmine matrix layer comprises 10-50% by weight of rivastigmine, 5-30% by weight of hydrophobic silica, and 30-80% by weight of an acrylic adhesive based on the total weight of the rivastigmine matrix layer.

### Claim 7 (depends on 6)

The rivastigmine patch of claim 6, wherein the acrylic adhesive is a random copolymer of 58-66 parts by weight of 2-ethylhexyl acrylate, 28-36 parts by weight of methyl acrylate, and 4-8 parts by weight of acrylic acid.

### Claim 8 (depends on 1)

The rivastigmine patch of claim 1, wherein the rivastigmine matrix layer further comprises an antioxidant.

### Claim 9 (depends on 1)

The rivastigmine patch of claim 1, wherein the rivastigmine patch comprises a release-controlling membrane that is an ethylene vinyl acetate film between the rivastigmine matrix layer and the self-adhesive matrix layer.

### Claim 10 (depends on 1)

The rivastigmine patch of claim 1, wherein the self-adhesive matrix layer comprises a mixture of two or more silicone adhesives having different physical properties.

### Claim 11 (depends on 10)

The rivastigmine patch of claim 10, wherein the self-adhesive matrix layer comprises a mixture of BIO-PSA 7-4201 and 7-4301.

### Claim 12 (depends on 11)

The rivastigmine patch of claim 11, wherein the self-adhesive matrix layer comprises a 1:1 weight ratio mixture of BIO-PSA 7-4201 and 7-4301.

### Claim 13 (depends on 5)

The rivastigmine patch of claim 5, wherein the content per patch area of the rivastigmine or a pharmaceutically acceptable salt thereof is 3.6 to 10.8 mg/cm2 based on the rivastigmine free base.

### Claim 14 (depends on 5)

The rivastigmine patch of claim 5, wherein the content per patch area of the rivastigmine or a pharmaceutically acceptable salt thereof is 5.4 to 9 mg/cm2 based on the rivastigmine free base.

### Claim 15 (depends on 5)

The rivastigmine patch of claim 5, wherein the hydrophobic silica is a hydrophobic fumed silica.
